文献速递肝病

采用护士主导的全州护理模式治疗囚犯丙型肝炎的结局

Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
PubMed 文献 · J Hepatol · 2019-01-14

在澳大利亚维多利亚州14所成人监狱开展为期13个月的前瞻性评估,评价护士主导、远程医疗支持的分散式丙肝治疗模式。416名囚犯纳入分析,按方案分析SVR12为96%(301/313),监狱间转移未降低SVR12,无治疗相关严重不良事件。

要点

  • 护士主导、远程医疗支持的分散式模式在监狱丙肝治疗中SVR12达96%(301/313,按方案分析)。
  • 26%的治疗疗程中发生监狱间转移,但未与较低的SVR12率相关。
  • 无治疗相关严重不良事件发生。

核心结论

  • 采用分散式、护士主导的护理模式治疗丙型肝炎高度有效,可覆盖大量囚犯。
  • 作者认为应考虑开展大规模监狱治疗项目,以支持丙型肝炎消除工作。

研究设计与样本

  • 在澳大利亚维多利亚州14所成人监狱开展为期13个月的前瞻性评估,评价护士主导、远程医疗支持的分散式丙肝护理模式的可行性与疗效。
  • 共416名囚犯纳入分析,主要终点为按方案分析的治疗结束后第12周持续病毒学应答(SVR12)。

主要发现

  • 纳入分析囚犯中位年龄41岁,90%为男性,50%为基因3型、44%为基因1型丙肝,21%有肝硬化。
  • 68%报告入狱前一个月有注射吸毒,54%正在接受阿片类替代治疗,86%报告此前从未接触专科HCV护理。
  • 治疗疗程8周占24%、12周占59%、24周占17%;按方案分析SVR12率为96%(301/313)。
  • 26%的治疗疗程中发生监狱间转移,但未与较低的SVR12率相关;无治疗相关严重不良事件发生。

临床怎么用

  • 作者认为应考虑开展大规模监狱治疗项目,以支持丙型肝炎消除工作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment programs for people who inject drugs (PWID), including prisoners, are important for achieving hepatitis C elimination targets. There are multiple barriers to treatment of hepatitis C in prisons, including access to specialist physicians, testing and antiviral therapy, short prison sentences, and frequent inter-prison transfer. We aimed to assess the effectiveness of a nurse-led model of care for the treatment of prisoners with hepatitis C. METHODS: A statewide program for assessment and management of hepatitis C was developed in Victoria, Australia to improve access to care for prisoners. This nurse-led model of care is supported by telemedicine to provide decentralized care within all prisons in the state. We prospectively evaluated the feasibility and efficacy of this nurse-led model of care for hepatitis C within the 14 adult prisons over a 13-month period. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12) using per protocol analysis. RESULTS: There were 416 prisoners included in the analysis. The median age was 41 years, 90% were male, 50% had genotype 3 and 44% genotype 1 hepatitis C and 21% had cirrhosis. Injecting drug use was reported by 68% in the month prior to prison entry, 54% were receiving opioid substitution therapy, and 86% reported never previously engaging with specialist HCV care. Treatment duration was 8 weeks in 24%, 12 weeks in 59%, and 24 weeks in 17% of treatment courses. The SVR12 rate was 96% (301/313) per protocol. Inter-prison transfer occurred during 26% of treatment courses but was not associated with lower SVR12 rates. No treatment-related serious adverse events occurred. CONCLUSION: Hepatitis C treatment using a decentralized, nurse-led model of care is highly effective and can reach large numbers of prisoners. Large scale prison treatment programs should be considered to support hepatitis C elimination efforts. LAY SUMMARY: There is a high burden of hepatitis C infection among prisoners worldwide. Prisoners who continue to inject drugs are also at risk of developing new infections. For this reason, the prison setting provides an opportunity to treat those people at greatest risk of infection and to stop transmission to others. We developed a new method of providing hepatitis C treatment to prisoners, in which nurses rather than doctors assessed prisoners locally at each prison site. Treatment was safe and most prisoners were cured. Such programs will contribute greatly to achieving the World Health Organization's hepatitis C elimination goals.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019. PMID: 30654067. doi:10.1016/j.jhep.2019.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。